Vonoprazan Fumarate

Hyderabad: Expanding its gastrointestinal portfolio in India, Dr Reddy’s Laboratories has announced the launch of its in-licensed novel molecule ‘ Tegoprazan ’, under the brand name ‘ Pcab ’ in India. Tegoprazan is a potassium-competitive acid blocker (P-CAB) which blocks H⁺/K⁺-ATPase enzyme , — a protein pomp responsible for the production of gastric acid. The drug is indicated for the treatment of acid peptic diseases (APD) such as Gastric Ulcer, Erosive Gastroesophageal Reflux Disease (GERD) and Non-Erosive Gastroesophageal Reflux Disease (NERD). Unlike the traditional proton pump inhibitors, Tegoprazan induces fast onset of action and can control gastric pH for a prolonged period. “Our partnership with HK inno.N Corporation for Tegoprazan brings together complementary strengths to enhance patient access to an innovative molecule that addresses critical gaps in acid peptic disease management and improves outcomes., “said M.V. Ramana, CEO Branded Markets (India and Emerging Markets), Dr.Reddy’s. Tegoprazan is developed by South Korea-based HK inno.N Corporation and in 2022, the Hyderabad-based drugmaker obtained the drug's India and select emerging markets commercial rights for an undisclosed amount. Currently the drug is approved in 21 countries and further registration in several countries is under process. Besides Tegoprazan, other approved P-CABs include 'Takecab,' marketed by Japanese biopharma company Takeda. However, Dr. Reddy’s formulation will be available in a 50 mg dose, whereas competing products are marketed in 10 mg and 20 mg strengths. According to the company release, APD affects around 38 per cent of the country’s total population. Data from the domestic market sales tracker PharmaTrac suggest that the gastrointestinal therapies represents the second largest drug market in India after cardiac, with a moving annual turnover of (MAT) Rs 28,263 crore as of August this year. By Online Bureau ,

FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom. While the breakout of holdings between funds and persons may appear different than prior filings, and the treatment of warrants may reduce certain percentages in the updated filings, these differences are due solely to clarifying changes in Frazier’s reporting approach and not to any sale of shares. About Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X. MEDIA CONTACTNick Benedetto1-877-742-8466media@phathompharma.com INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@phathompharma.com © 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.